ES2181915T3 - Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones. - Google Patents

Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.

Info

Publication number
ES2181915T3
ES2181915T3 ES96936385T ES96936385T ES2181915T3 ES 2181915 T3 ES2181915 T3 ES 2181915T3 ES 96936385 T ES96936385 T ES 96936385T ES 96936385 T ES96936385 T ES 96936385T ES 2181915 T3 ES2181915 T3 ES 2181915T3
Authority
ES
Spain
Prior art keywords
ctla
combination
csf
treat infections
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96936385T
Other languages
English (en)
Inventor
Jacques Banchereau
Odille Djossou
Leopoldo Flores-Romo
Francois Fossiez
Pierre Golstein
Mala Krishna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Merck Sharp and Dohme Corp
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Schering Corp filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of ES2181915T3 publication Critical patent/ES2181915T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSICIONES Y METODOS PARA USAR CTLA-8 Y TRATAR TRASTORNOS FISIOLOGICOS EN UN INDIVIDUO. LOS METODOS COMPRENDEN LA ADMINISTRACION DE UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE CTLA-8 EN MONOTERAPIA O COMBINACION CON OTROS AGENTES TERAPEUTICOS; O UN ANTAGONISTA DEL CTLA-8
ES96936385T 1995-10-27 1996-10-23 Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones. Expired - Lifetime ES2181915T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US590995P 1995-10-27 1995-10-27
US56974295A 1995-12-08 1995-12-08

Publications (1)

Publication Number Publication Date
ES2181915T3 true ES2181915T3 (es) 2003-03-01

Family

ID=26674918

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96936385T Expired - Lifetime ES2181915T3 (es) 1995-10-27 1996-10-23 Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.

Country Status (11)

Country Link
EP (1) EP0862454B1 (es)
JP (2) JP3253633B2 (es)
AT (1) ATE222768T1 (es)
AU (1) AU7439996A (es)
CA (1) CA2235951C (es)
DE (1) DE69623316T2 (es)
DK (1) DK0862454T3 (es)
ES (1) ES2181915T3 (es)
HK (1) HK1015692A1 (es)
PT (1) PT862454E (es)
WO (1) WO1997015320A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
CA2646478A1 (en) 2006-03-10 2007-09-20 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
US7790163B2 (en) 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
EP2392597B1 (en) 2007-04-27 2014-04-02 ZymoGenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
BRPI0919531A2 (pt) 2008-09-29 2015-12-08 Roche Glycart Ag anticorpos contra il17 humana e usos dos mesmos
US20100310502A1 (en) * 2009-06-09 2010-12-09 Anders Linden Method of treating local infections in mammals
BR112014024903A2 (pt) 2012-04-05 2017-07-11 Hoffmann La Roche anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96477A0 (en) * 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
WO1992003151A1 (en) * 1990-08-23 1992-03-05 Cetus Corporation Uses of recombinant colony stimulating factor-1
US6562333B1 (en) * 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
EP0734265A1 (en) * 1993-12-13 1996-10-02 Novartis AG Il-6 therapy

Also Published As

Publication number Publication date
HK1015692A1 (en) 1999-10-22
CA2235951C (en) 2003-04-01
WO1997015320A1 (en) 1997-05-01
EP0862454A1 (en) 1998-09-09
JP2002145799A (ja) 2002-05-22
PT862454E (pt) 2002-11-29
DK0862454T3 (da) 2002-12-30
AU7439996A (en) 1997-05-15
DE69623316T2 (de) 2003-04-17
JPH10512293A (ja) 1998-11-24
CA2235951A1 (en) 1997-05-01
ATE222768T1 (de) 2002-09-15
DE69623316D1 (de) 2002-10-02
JP3253633B2 (ja) 2002-02-04
EP0862454B1 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
ES2177780T3 (es) Medicamentos para el tratamiento de enfermedades autoinmunes usando interferon tau.
MY119403A (en) Novel compounds with analgesic effect.
MY115662A (en) Novel compounds with analgesic effect
HK1030157A1 (en) Use of consensus interferon and compositions comprising consensus interferon.
BR9006924A (pt) Formulacao para tratamento de sintomas e doencas,uso de formulacao para o tratamento de sintomas e doencas,metodo para o tratamento de sintomas e doencas,distribuicao de agentes medicinais e terapeuticos para o tratamento de sintomas e doencas e combinacao para administracao em mamiferos
ATE91233T1 (de) Antivirale pharmazeutische zusammensetzungen und ihrer verwendung.
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
TR199802769T2 (xx) Terpenoid bileşikler ile antihistaminik bileşiklerin bir kombinasyonunu ihtiva eden topikal bileşim.
CA2163118A1 (en) Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
ES2181915T3 (es) Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
DK0680323T3 (da) Synergistisk kombination med antagonistvirkning ved NK1- og Nk2-receptorer.
ES2089286T3 (es) Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos.
ATE81775T1 (de) Pharmazeutische zusammensetzungen.
SE9504662D0 (sv) New compounds
WO2000061171A3 (en) Uses of mammalian ox2 protein and related reagents
IT1251993B (it) Composizioni farmaceutiche ad uso orale,a base di esteri di gangliosidi,per il trattamento di neuropatie del sistema nervoso periferico
UA26886C2 (uk) Солі 1,3-діарил-4,5-поліметилеhімідазолію, що виявляють аhальгезуючу активhість
ITMI922216A0 (it) Nitrobenzoilalanine procedimento per la loro preparazione loro uso come agenti terapeutici e composizioni farmaceutiche che le contengono